Navigation Links
Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco
Date:10/13/2010

s/pharmasia.aspx) (Oct. 25-26). This year's Summit will bring top biopharma leaders from Asia and the U.S. to San Francisco to share what works and what doesn't in China, India, Japan and the Pacific Rim.

At the PharmAsia Summit, you'll hear Asia strategies and case studies from industry leading experts on dealmaking, commercial strategy, outsourcing, regulatory risks, IP protection, and pricing and reimbursement. Confirmed speakers include:

- Biogen Idec's Gunther Winkler, Senior VP Asia Pacific & Global Government Strategy - Merck's Ramesh Subrahmanian, Senior VP & President of Asia Pacific Human Health - Takeda Research Investment CEO Graeme Martin - Pfizer's Neil Gibson, CSO Oncology Research - Gilead's Clifford Samuel, VP International Access - Advinus Therapeutics CEO Rashmi Barbhaiya - Onyx CEO Anthony Coles - S*Bio CEO Jan-Anders Karlsson - Piramal Life Sciences Managing Director Somesh Sharma - IMS Asia Pacific VP Jan Willem Eleveld - Piper Jaffrey China Healthcare Analyst Hongbo Lu Plus, you'll have a rare opportunity to speak with top Asia regulators, including: - U.S. FDA China Office Director Chris Hickey - U.S. FDA India Office Director Bruce Ross - Shanghai FDA Deputy Director General Yi Chengdong - Korea FDA's Hong Soon-Wook, Director Pharmaceutical Safety Policy

"PharmAsia Summit is a rare opportunity for U.S. biopharma execs to gain an insider's perspective on the most important developments in China, India and Japan without having to cross the Pacific," said Gerry Stoia, president of Elsevier Business Intelligence. "Given the increasing importance of markets like China and India to the biopharma industry, we are honored to host this distinguished group in San Francisco, and hope the Summit will contribute to the dialogue between U.S. and Asia biopharma leaders."

Attendees will in addition learn the latest on China healthcare reform, U.S. FDA actions in China and India, ca
'/>"/>

SOURCE Elsevier
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
2. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
3. PDL BioPharma Completes October 1 Special Dividend Payment
4. Genesis Biopharma Announces $700K Private Financing
5. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
6. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
7. Helix BioPharma Approved for NYSE Amex Listing
8. PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes
9. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
10. Reportlinker Adds Advances in Biopharmaceutical Technology in China
11. PDL BioPharma Announces Retirement of $61.6 Million of 2.75% Convertible Notes due August 2023 for Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 As pet owners drew up their lists of ... wrote: "Take better care of my furry companion." Nowadays there are ... top-brand carrying cases to take the little canine or feline darlings ... compelled to buy some pricey toys at the pet store. But ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 iLab Solutions, the ... as the new Director of Product Strategy. In this role, ... as iLab sub-teams to guide in the development of iLab ... provides the maximum possible benefit to the scientific community by ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... call and webcast to begin after markets close at 2:00 p.m. PT ... ... Masimo Corporation,(Nasdaq: MASI ), the inventor of Pulse CO-Oximetry and,Measure-Through-Motion- ... the period ended,September 27, 2008 after the market closes on Monday, October ...
... Oct. 15 PURE Bioscience (Nasdaq:,PURE), creators of ... revenues for the fiscal year ended July 31, ... with $336,400 in the,prior fiscal year. The Company ... or $(0.24) per share, compared with a loss ...
... Agency Expanding Industry Connections, MOUNTAINSIDE, N.J., Oct. ... medical education company,today announced the hiring of Todd ... leverage his experience in medical education and,publishing as ... L&M, he,served as Manager of Publication Sales at ...
Cached Biology Technology:Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008 2PURE Bioscience Reports Fourth Quarter and Year End Results 2PURE Bioscience Reports Fourth Quarter and Year End Results 3PURE Bioscience Reports Fourth Quarter and Year End Results 4PURE Bioscience Reports Fourth Quarter and Year End Results 5PURE Bioscience Reports Fourth Quarter and Year End Results 6PURE Bioscience Reports Fourth Quarter and Year End Results 7L&M Healthcare Communications LLC Expands Client Services With Executive Team Expansion 2
(Date:7/9/2014)... Bacterial infections usually announce themselves with pain and fever but ... are those that are sneaky and hard to beat. Now, ... the form of tiny DNA pyramids. Published in the journal ... the nanopyramids can flag bacteria and kill more of them ... note that some infectious pathogens can lie in wait, undetectable ...
(Date:7/9/2014)... by researchers at the NIH,s National Center ... collaborators to treat sickle cell disease has ... The drug candidate, Aes-103, is the first ... mechanism of sickle cell disease. Baxter now ... for regulatory approval and commercialization. , Sickle ...
(Date:7/9/2014)... vitamin D in their blood are more likely to survive ... highest levels of vitamin D have half the risk of ... reveal. , The study is the first to correlate total ... their diagnosis which includes that produced after exposure to ... long term survival prospects. , The University of Edinburgh ...
Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... Foundation announced that five scientists with novel approaches to ... Damon Runyon-Rachleff Innovation Award. The grant of $450,000 ... career scientists whose projects have the potential to significantly ... The 2011 Damon Runyon-Rachleff Innovators are: ...
... Frontotemporal dementia is caused by a breakdown of nerve ... brain (fronto-temporal lobe), which leads to, among other symptoms, ... some forms of frontotemporal dementia is a genetically determined ... Dr. Anja Capell and Prof. Christian Haass have now ...
... Invasive plant species are a serious environmental, economic and ... native biodiversity and ecosystem functions, such as nutrient cycling. ... why some species dominate new habitats over native plants ... but rarely tested assumption, say biologists, is that these ...
Cached Biology News:Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 2Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 3Malaria medication may help against 1 type of frontotemporal dementia 2Home and away: Are invasive plant species really that special? 2
Rabbit polyclonal to Staphylococcus Enterotoxin E (Biotin) ( Abpromise for all tested applications)....
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
... first fully genetically encoded fluorescent sensor capable ... peroxide (H2O2), one of the main ROS ... of yellow fluorescent protein inserted into the ... (OxyR-RD), HyPer demonstrates submicromolar affinity to H2O2 ...
Biology Products: